Alpha emitter radium-223 and survival in metastatic prostate cancer.

Parker, C; Nilsson, S; Heinrich, D; Helle, S; O'Sullivan, J; Fosså, S; Chodacki, A; Wiechno, P; Logue, John P; Seke, M; Widmark, A; Johannessen, D; Hoskin, P; Bottomley, D; James, N; Solberg, A; Syndikus, I; Kliment, J; Wedel, S; Boehmer, S; Dall'Oglio, M; Franzén, L; Coleman, R; Vogelzang, N; O'Bryan-Tear, C; Staudacher, K; Garcia-Vargas, J; Shan, M; Bruland, Ø; Sartor, O

Affiliation

Royal Marsden National Health Service Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom.

Issue Date

2013-07-18

Metadata

Show full item record

Abstract

Radium-223 dichloride (radium-223), an alpha emitter, selectively targets bone metastases with alpha particles. We assessed the efficacy and safety of radium-223 as compared with placebo, in addition to the best standard of care, in men with castration-resistant prostate cancer and bone metastases.

Citation

Alpha emitter radium-223 and survival in metastatic prostate cancer. 2013, 369 (3):213-23 N Engl J Med

Journal

New England Journal of Medicine

URI

http://hdl.handle.net/10541/302266

DOI

10.1056/NEJMoa1213755

PubMed ID

23863050

Type

Article

Language

ISSN

1533-4406

Collections

All Christie Publications